DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
Download on the App Store
Screenshot of DeepNewz app showing story detail view.
Feb 28, 03:15 PM
Novavax Misses Estimates, Q4 Revenues $291M, FY'23 Revenue $1B
Economics
Business

Novavax Misses Estimates, Q4 Revenues $291M, FY'23 Revenue $1B

Authors
  • Reuters
  • CNBC
  • Barron's
11

Several companies including PubMatic Inc, TransMedics, PAR Technology Corporation, SI-BONE, Inc, Cytokinetics, Kiniksa Pharmaceuticals, Novavax, Mirum Pharma, Marathon Digital Holdings, Verano, and Trulieve have reported their fourth quarter and fiscal year 2023 financial results. Novavax missed quarterly estimates but narrowed losses, with revenue of $291 million in Q4 and $1 billion for FY'23, providing guidance of $800 million to $1 billion for FY'24.

#PubMatic Inc#TransMedics#PAR Technology Corporation#Cytokinetics#Kiniksa Pharmaceuticals#Novavax#Mirum Pharma#Marathon Digital Holdings#Verano#Trulieve
Tech /Company Earnings
Written with ChatGPT (GPT-3).

Sources

Additional media

Image #1 for story novavax-misses-estimates-q4-revenues-291m-fy-23-revenue-1b
Image #2 for story novavax-misses-estimates-q4-revenues-291m-fy-23-revenue-1b
Image #3 for story novavax-misses-estimates-q4-revenues-291m-fy-23-revenue-1b
Image #4 for story novavax-misses-estimates-q4-revenues-291m-fy-23-revenue-1b
Image #5 for story novavax-misses-estimates-q4-revenues-291m-fy-23-revenue-1b
Image #6 for story novavax-misses-estimates-q4-revenues-291m-fy-23-revenue-1b
Image #7 for story novavax-misses-estimates-q4-revenues-291m-fy-23-revenue-1b
Image #8 for story novavax-misses-estimates-q4-revenues-291m-fy-23-revenue-1b
Image #9 for story novavax-misses-estimates-q4-revenues-291m-fy-23-revenue-1b
Image #10 for story novavax-misses-estimates-q4-revenues-291m-fy-23-revenue-1b
Image #11 for story novavax-misses-estimates-q4-revenues-291m-fy-23-revenue-1b